VERTEX PHARMACEUTICALS INC / MA Insider Trading for February 2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in VERTEX PHARMACEUTICALS INC / MA.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in VERTEX PHARMACEUTICALS INC / MA for February 2019.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 22 2019 | VRTX | VERTEX PHARMACEUTI ... | CARNEY LLOYD | Director | Grant | A | 0.00 | 2,161 | 0 | 2,161 | 0 to 2.2 K |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 188.70 | 160 | 30,192 | 17,759 | 17.9 K to 17.8 K (-0.89 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 187.10 | 984 | 184,106 | 17,919 | 18.9 K to 17.9 K (-5.21 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 186.72 | 1,668 | 311,449 | 18,903 | 20.6 K to 18.9 K (-8.11 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 188.54 | 400 | 75,416 | 35,003 | 35.4 K to 35 K (-1.13 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 187.42 | 600 | 112,452 | 35,403 | 36 K to 35.4 K (-1.67 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 186.79 | 4,624 | 863,717 | 36,003 | 40.6 K to 36 K (-11.38 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 188.61 | 1,200 | 226,332 | 106,195 | 107.4 K to 106.2 K (-1.12 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 187.43 | 2,700 | 506,061 | 107,395 | 110.1 K to 107.4 K (-2.45 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 186.80 | 17,097 | 3,193,720 | 110,095 | 127.2 K to 110.1 K (-13.44 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 188.49 | 100 | 18,849 | 13,736 | 13.8 K to 13.7 K (-0.72 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 187.27 | 202 | 37,829 | 13,836 | 14 K to 13.8 K (-1.44 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Sell | S | 186.75 | 1,186 | 221,486 | 14,038 | 15.2 K to 14 K (-7.79 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 188.59 | 400 | 75,436 | 31,553 | 32 K to 31.6 K (-1.25 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 187.40 | 651 | 121,997 | 31,953 | 32.6 K to 32 K (-2.00 %) |
| Feb 21 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 186.81 | 4,573 | 854,282 | 32,604 | 37.2 K to 32.6 K (-12.30 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Option Exercise | A | 187.53 | 25,026 | 4,693,126 | 25,026 | |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Grant | A | 0.00 | 9,799 | 0 | 75,260 | 65.5 K to 75.3 K (+14.97 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Grant | A | 0.00 | 10,126 | 0 | 65,461 | 55.3 K to 65.5 K (+18.30 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Grant | A | 0.00 | 17,298 | 0 | 55,335 | 38 K to 55.3 K (+45.48 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Option Exercise | A | 187.53 | 7,449 | 1,396,911 | 7,449 | |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Grant | A | 0.00 | 5,000 | 0 | 24,786 | 19.8 K to 24.8 K (+25.27 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Grant | A | 0.00 | 2,917 | 0 | 19,786 | 16.9 K to 19.8 K (+17.29 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Grant | A | 0.00 | 4,220 | 0 | 16,869 | 12.6 K to 16.9 K (+33.36 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Option Exercise | A | 187.53 | 72,647 | 13,623,492 | 72,647 | |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Grant | A | 0.00 | 28,444 | 0 | 238,623 | 210.2 K to 238.6 K (+13.53 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Grant | A | 0.00 | 31,498 | 0 | 210,179 | 178.7 K to 210.2 K (+17.63 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Grant | A | 0.00 | 53,816 | 0 | 178,681 | 124.9 K to 178.7 K (+43.10 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | A | 187.53 | 20,855 | 3,910,938 | 20,855 | |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Grant | A | 0.00 | 8,166 | 0 | 52,763 | 44.6 K to 52.8 K (+18.31 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Grant | A | 0.00 | 8,438 | 0 | 44,597 | 36.2 K to 44.6 K (+23.34 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Option Exercise | A | 187.53 | 25,026 | 4,693,126 | 25,026 | |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Grant | A | 0.00 | 9,799 | 0 | 15,224 | 5.4 K to 15.2 K (+180.63 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Kewalramani Reshma | EVP and CMO | Grant | A | 0.00 | 3,516 | 0 | 5,425 | 1.9 K to 5.4 K (+184.18 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | A | 187.53 | 20,855 | 3,910,938 | 20,855 | |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 8,166 | 0 | 70,133 | 62 K to 70.1 K (+13.18 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 8,438 | 0 | 61,967 | 53.5 K to 62 K (+15.76 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Grant | A | 0.00 | 14,416 | 0 | 53,529 | 39.1 K to 53.5 K (+36.86 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | A | 187.53 | 25,026 | 4,693,126 | 25,026 | |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Grant | A | 0.00 | 9,799 | 0 | 71,937 | 62.1 K to 71.9 K (+15.77 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Grant | A | 0.00 | 8,438 | 0 | 62,138 | 53.7 K to 62.1 K (+15.71 %) |
| Feb 08 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Grant | A | 0.00 | 17,298 | 0 | 53,700 | 36.4 K to 53.7 K (+47.52 %) |
| Feb 07 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Option Exercise | M | 91.05 | 1,289 | 117,363 | 5,157 | |
| Feb 07 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 193.00 | 1,289 | 248,777 | 12,649 | 13.9 K to 12.6 K (-9.25 %) |
| Feb 07 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Buy | M | 91.05 | 1,289 | 117,363 | 13,938 | 12.6 K to 13.9 K (+10.19 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Option Exercise | M | 91.05 | 2,155 | 196,213 | 8,622 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Option Exercise | M | 86.52 | 1,942 | 168,022 | 15,533 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 187.30 | 3,625 | 678,963 | 38,037 | 41.7 K to 38 K (-8.70 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 186.55 | 5,000 | 932,750 | 41,662 | 46.7 K to 41.7 K (-10.72 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 187.23 | 1,035 | 193,783 | 46,662 | 47.7 K to 46.7 K (-2.17 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 186.52 | 1,120 | 208,902 | 47,697 | 48.8 K to 47.7 K (-2.29 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Buy | M | 91.05 | 2,155 | 196,213 | 48,817 | 46.7 K to 48.8 K (+4.62 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 187.35 | 742 | 139,014 | 46,662 | 47.4 K to 46.7 K (-1.57 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 186.57 | 1,200 | 223,884 | 47,404 | 48.6 K to 47.4 K (-2.47 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Buy | M | 86.52 | 1,942 | 168,022 | 48,604 | 46.7 K to 48.6 K (+4.16 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 86.52 | 1,554 | 134,452 | 12,426 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 91.05 | 2,155 | 196,213 | 8,621 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 109.14 | 4,250 | 463,845 | 0 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 188.07 | 300 | 56,421 | 36,402 | 36.7 K to 36.4 K (-0.82 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 186.84 | 4,044 | 755,581 | 36,702 | 40.7 K to 36.7 K (-9.92 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 186.10 | 12,565 | 2,338,347 | 40,746 | 53.3 K to 40.7 K (-23.57 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 184.81 | 1,400 | 258,734 | 53,311 | 54.7 K to 53.3 K (-2.56 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 86.52 | 1,554 | 134,452 | 54,711 | 53.2 K to 54.7 K (+2.92 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 91.05 | 2,155 | 196,213 | 53,157 | 51 K to 53.2 K (+4.23 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 109.41 | 4,250 | 464,993 | 51,002 | 46.8 K to 51 K (+9.09 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Option Exercise | M | 86.52 | 809 | 69,995 | 6,472 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 188.33 | 120 | 22,600 | 12,649 | 12.8 K to 12.6 K (-0.94 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 186.85 | 2,268 | 423,776 | 12,769 | 15 K to 12.8 K (-15.08 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 186.17 | 450 | 83,777 | 15,037 | 15.5 K to 15 K (-2.91 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 185.11 | 600 | 111,066 | 15,487 | 16.1 K to 15.5 K (-3.73 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 189.19 | 809 | 153,055 | 16,087 | 16.9 K to 16.1 K (-4.79 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Buy | M | 86.52 | 809 | 69,995 | 16,896 | 16.1 K to 16.9 K (+5.03 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 187.91 | 900 | 169,119 | 124,865 | 125.8 K to 124.9 K (-0.72 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 186.70 | 12,951 | 2,417,952 | 125,765 | 138.7 K to 125.8 K (-9.34 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 186.10 | 17,099 | 3,182,124 | 138,716 | 155.8 K to 138.7 K (-10.97 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 184.99 | 1,300 | 240,487 | 155,815 | 157.1 K to 155.8 K (-0.83 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | M | 86.52 | 2,330 | 201,592 | 18,639 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | M | 91.05 | 1,796 | 163,526 | 7,184 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 189.19 | 2,330 | 440,813 | 39,113 | 41.4 K to 39.1 K (-5.62 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Buy | M | 86.52 | 2,330 | 201,592 | 41,443 | 39.1 K to 41.4 K (+5.96 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 189.19 | 1,796 | 339,785 | 39,113 | 40.9 K to 39.1 K (-4.39 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Buy | M | 91.05 | 1,796 | 163,526 | 40,909 | 39.1 K to 40.9 K (+4.59 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | M | 86.52 | 2,330 | 201,592 | 18,639 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 189.19 | 2,330 | 440,813 | 36,159 | 38.5 K to 36.2 K (-6.05 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Buy | M | 86.52 | 2,330 | 201,592 | 38,489 | 36.2 K to 38.5 K (+6.44 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Option Exercise | M | 91.05 | 2,155 | 196,213 | 8,622 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Option Exercise | M | 86.52 | 1,942 | 168,022 | 15,533 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 187.30 | 3,625 | 678,963 | 38,037 | 41.7 K to 38 K (-8.70 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 186.55 | 5,000 | 932,750 | 41,662 | 46.7 K to 41.7 K (-10.72 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 187.23 | 1,035 | 193,783 | 46,662 | 47.7 K to 46.7 K (-2.17 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 186.52 | 1,120 | 208,902 | 47,697 | 48.8 K to 47.7 K (-2.29 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Buy | M | 91.05 | 2,155 | 196,213 | 48,817 | 46.7 K to 48.8 K (+4.62 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 187.35 | 742 | 139,014 | 46,662 | 47.4 K to 46.7 K (-1.57 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 186.57 | 1,200 | 223,884 | 47,404 | 48.6 K to 47.4 K (-2.47 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Buy | M | 86.52 | 1,942 | 168,022 | 48,604 | 46.7 K to 48.6 K (+4.16 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 86.52 | 1,554 | 134,452 | 12,426 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 91.05 | 2,155 | 196,213 | 8,621 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 109.14 | 4,250 | 463,845 | 0 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 188.07 | 300 | 56,421 | 36,402 | 36.7 K to 36.4 K (-0.82 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 186.84 | 4,044 | 755,581 | 36,702 | 40.7 K to 36.7 K (-9.92 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 186.10 | 12,565 | 2,338,347 | 40,746 | 53.3 K to 40.7 K (-23.57 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 184.81 | 1,400 | 258,734 | 53,311 | 54.7 K to 53.3 K (-2.56 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 86.52 | 1,554 | 134,452 | 54,711 | 53.2 K to 54.7 K (+2.92 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 91.05 | 2,155 | 196,213 | 53,157 | 51 K to 53.2 K (+4.23 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 109.41 | 4,250 | 464,993 | 51,002 | 46.8 K to 51 K (+9.09 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Option Exercise | M | 86.52 | 809 | 69,995 | 6,472 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 188.33 | 120 | 22,600 | 12,649 | 12.8 K to 12.6 K (-0.94 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 186.85 | 2,268 | 423,776 | 12,769 | 15 K to 12.8 K (-15.08 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 186.17 | 450 | 83,777 | 15,037 | 15.5 K to 15 K (-2.91 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 185.11 | 600 | 111,066 | 15,487 | 16.1 K to 15.5 K (-3.73 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Sell | S | 189.19 | 809 | 153,055 | 16,087 | 16.9 K to 16.1 K (-4.79 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Interim CFO | Buy | M | 86.52 | 809 | 69,995 | 16,896 | 16.1 K to 16.9 K (+5.03 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 187.91 | 900 | 169,119 | 124,865 | 125.8 K to 124.9 K (-0.72 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 186.70 | 12,951 | 2,417,952 | 125,765 | 138.7 K to 125.8 K (-9.34 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 186.10 | 17,099 | 3,182,124 | 138,716 | 155.8 K to 138.7 K (-10.97 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 184.99 | 1,300 | 240,487 | 155,815 | 157.1 K to 155.8 K (-0.83 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | M | 86.52 | 2,330 | 201,592 | 18,639 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | M | 91.05 | 1,796 | 163,526 | 7,184 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 189.19 | 2,330 | 440,813 | 39,113 | 41.4 K to 39.1 K (-5.62 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Buy | M | 86.52 | 2,330 | 201,592 | 41,443 | 39.1 K to 41.4 K (+5.96 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 189.19 | 1,796 | 339,785 | 39,113 | 40.9 K to 39.1 K (-4.39 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Buy | M | 91.05 | 1,796 | 163,526 | 40,909 | 39.1 K to 40.9 K (+4.59 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | M | 86.52 | 2,330 | 201,592 | 18,639 | |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 189.19 | 2,330 | 440,813 | 36,159 | 38.5 K to 36.2 K (-6.05 %) |
| Feb 06 2019 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Buy | M | 86.52 | 2,330 | 201,592 | 38,489 | 36.2 K to 38.5 K (+6.44 %) |